Tuti Endarwati, Khamdiyah Indah Kurniasih, Fauziah Fauziah, Sunarti Sunarti, Muh Agus Salim
Stroke is the third most common cause of disability and the second most common cause of death globally. Between 1990 and 2019, its prevalence increased by 70%. The prevalence of stroke increased from 7% in 2013 to 10.9% in 2018 in Indonesia. Because antiplatelet medication does not improve platelet aggregation, ischemic stroke patients have significant death and disability rates. The efficacy of cilostazol, clopidogrel, and aspirin in ischemic stroke patients is compared in this study. 205 patients who satisfied the inclusion criteria from 919 stroke cases at RSUD Margono Soekarjo in 2023 were the subjects of a cross-sectional retrospective design using purposive sampling. The Kruskal-Wallis test and mean difference tests were used to examine the results of the therapy. Outperforming aspirin and cilostazol, clopidogrel (75 mg) were the most widely used medication (38.6%) and produced the best results, considerably enhancing PT (1 s), APTT (0.872 s), and lowering leukocytes (2.956) and platelets (3.035). Significant variations in leukocyte (p=0.045) and platelet (p=0.040) levels were found using statistical tests. When it came to enhancing coagulation markers and lowering inflammation, clopidogrel proved to be a more effective therapy option for ischemic stroke. © The Authors, published by EDP Sciences.
Pharmacy Departemen, Faculty of Health, Universitas Harapan Bangsa, Central Java, Indonesia; Pharmacy Departemen, Faculty of Health, Universitas Al-Irsyad Cilacap, Central Java, Indonesia
Research at a Glance
Register to unlock
Topics & SDG Alignment
Register to unlock
Collaboration
Register to unlock
Author Profile (Selected)
Register to unlock
References Overview
Register to unlock
Journal & Source
Register to unlock
Metadata & Integrity
Register to unlock